Azidus Brasil clinical trials
Also known as AZD CRO.
The registry lists 80 studies whose lead sponsor is Azidus Brasil. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 3, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 80studies on the registry
- 5open to participants now
- 4phase 3 studies under way
- 1reach primary completion within a year
Get an email when these change. Save the Azidus Brasil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Azidus Brasil’s studies test, most open studies first — 42 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- Immunoglobulin G2 in phase 32 open · 2
- Immunoglobulins, Intravenous2 in phase 32 open · 2
- Epoetin Alfa1 in phase 30 open · 6
- nitazoxanide2 in phase 30 open · 4
- Heparin1 in phase 30 open · 3
- 0 open · 2
- Chondroitin Sulfates2 in phase 30 open · 2
- Dexamethasone2 in phase 30 open · 2
- 0 open · 2
- 0 open · 2
Show 20 moreShow fewer
- (+)-pseudoephedrine sulfate1 in phase 30 open · 1
- Asian ginseng1 in phase 30 open · 1
- Aspirin1 in phase 30 open · 1
- 0 open · 1
- Beclomethasone1 in phase 30 open · 1
- botulinum toxin type A1 in phase 30 open · 1
- Citric Acid1 in phase 30 open · 1
- Clemastine1 in phase 30 open · 1
- Clobetasol1 in phase 30 open · 1
- Clotrimazole1 in phase 30 open · 1
- Collagenase1 in phase 30 open · 1
- 0 open · 1
- Gentamicins1 in phase 30 open · 1
- Glucosamine1 in phase 30 open · 1
- halobetasol1 in phase 30 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- Loratadine1 in phase 30 open · 1
- 0 open · 1
The first 30 of 42; every drug is on its own page, and each page lists its sponsors.
Coming up
1 of Azidus Brasil’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
- Dec 2026Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and InfluenzaPhase 3 · NCT06817096
Add it to your calendar (.ics) → With an account.
All 80 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 1510
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 126
By the year each study started; 2 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Azidus Brasil.
- Azidus Brasil80 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 80. Browse all 80 →
- IVIG Boya: Safety, Efficacy, and PharmacokineticsNot yet recruitingNCT06150833Phase 3
- Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and InfluenzaNot yet recruitingNCT06817096Phase 3
- Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIGNot yet recruitingNCT06089122Phase 3
- Safety of UFRJvac, Trivalent COVID-19 VaccineNot yet recruitingNCT06303635
- Efficacy and Safety of NestaCell® in Huntington's DiseaseNot yet recruitingNCT06097780Phase 3
- Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's DiseaseCompletedNCT03252535Phase 2
- Efficacy And Safety Of Probiatop In The Treatment Of Digestive SymptomsCompletedNCT05603403Phase 4
- Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19SuspendedNCT04329572Early Phase 1
- Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19SuspendedNCT04348474Early Phase 1
- Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous UlcersSuspendedNCT00701974Phase 2/3
- Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®SuspendedNCT01086982Phase 1
- Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.SuspendedNCT01229072Phase 2/3
- Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two DrugsWithdrawnNCT01228643Phase 3
- Sodic Heparin Effectiveness of the Treatment of BurnsWithdrawnNCT00701623Phase 2/3
- Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of MelasmaSuspendedNCT00717652Phase 2/3
- Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone FuroateSuspendedNCT01228656Phase 2
- Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne ContaminatedSuspendedNCT01244256Phase 2/3
- Efficacy and Safety of the Association Drugs in Patients With Allergic DermatitisWithdrawnNCT01125761Phase 3
- Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.CompletedNCT03572647Phase 1
- Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract SurgeryCompletedNCT01227876Phase 3
- Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.SuspendedNCT01666249Phase 3
- Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's DiseaseStatus unknownNCT02728115Phase 1
- Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single DoseCompletedNCT01692158Phase 1
- Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + HydrochlorothiazideCompletedNCT01692717Phase 1
- Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous AdministrationCompletedNCT01692171Phase 1
- Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19Status unknownNCT04423861Phase 3
- Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic RhinitisWithdrawnNCT01055756Phase 3
- PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.CompletedNCT01685333Phase 1
- Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.Status unknownNCT04219241Phase 2/3
- Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19WithdrawnNCT04435314Phase 2
- PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human RecombinantCompletedNCT01685359Phase 1
- NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 PneumoniaCompletedNCT04315987Phase 2
- Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19CompletedNCT04348409Not applicable
- Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 PatientsWithdrawnNCT04441398Phase 2/3
- Study To Evaluate The Sensitivity Of The Linda Thermal DeviceStatus unknownNCT05009277
- Safety and Immunogenicity of the RNA MCTI CIMATEC HDT VaccineStatus unknownNCT05542693Phase 2
- Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 PatientsStatus unknownNCT04352465Phase 1/2
- Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.TerminatedNCT01695759Phase 3
- Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.CompletedNCT01549301Phase 1
- Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.CompletedNCT01228630Phase 3
- Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression LinesCompletedNCT01180348Phase 3
- Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.CompletedNCT01480778Phase 3
- Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical PatientsWithdrawnNCT00912483Phase 3
- Effectiveness of Glucosamine + Chondroitin in OsteoarthrosisCompletedNCT00860873Phase 3
- Efficacy and Safety of Sodium Heparin (Hipolabor) in PatientsCompletedNCT00894673Phase 3
- Efficacy and Safety of Sodium Heparin (Eurofarma)CompletedNCT00894829Phase 3
- Efficacy and Safety of Sodium Heparin in PatientsCompletedNCT00894959Phase 3
- Efficacy and Safety of Sodium HeparinCompletedNCT00894985Phase 3
- Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous UlcerationCompletedNCT00857688Phase 3
- Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy SubjectsCompletedNCT01074593Phase 1